Study-specific site selection support for clinical trials
Make faster, more defensible site decisions for your next clinical trial
Catχi helps sponsor-side teams evaluate sites using public trial data and explainable signals, so they can prioritize stronger sites earlier and reduce the risk of slow recruitment.
The challenge
Site selection is still too often driven by fragmented data and legacy assumptions
Sponsor-side teams often have to make high-stakes site decisions before they have a clear view of which sites and investigators are likely to start efficiently, recruit relevant patients, and stay productive over time.
Catχi is built to support earlier, more structured site prioritization for a specific protocol, indication, geography, and patient profile.
How it works
Share the study context
Provide the key study details, including indication, geography, and other factors that matter for site selection.
Review relevant site signals
Catχi reviews public trial data and site-level signals to help compare likely fit, operational risk, and recruitment relevance.
Receive a practical recommendation set
You receive a structured output to support site prioritization and next-step decision-making.
What you receive
A practical output your team can review and use
Depending on the engagement, Catχi can provide a study-specific review that includes:
- a ranked site shortlist
- geography-level comparisons for similar trial patterns
- risk flags for startup or enrollment
- notes on likely fit and likely friction
- recommendations on which sites to prioritize, monitor, or re-evaluate
Start with a 1-page site risk analysis before deciding whether a broader engagement makes sense.
Why teams use Catχi
More structured decisions
Move beyond generic feasibility assumptions and compare sites using study-specific signals.
Earlier risk visibility
Flag possible startup and recruitment issues before they become more expensive and harder to correct.
Better use of team attention
Help teams spend less time on weak candidates and more time on sites worth deeper follow-up.
Who it is for
Built for sponsor-side teams that need a stronger site-selection starting point
Catχi is especially relevant for teams that cannot afford slow site decisions or broad trial-and-error across too many sites.
Why Catχi
Built by experts in medicine and AI
Catχi is led by founders with deep experience across medicine, clinical research, and AI. Dora Morozova is a board-certified hematologist with more than 7 years of scientific experience, clinical-trials expertise, and recognition from the European Society on Thrombosis and Haemostasis. Alex Martyanov is a biophysicist and computer-vision specialist recognized by the American Society of Hematology, with more than 40 publications.
That combination helps turn public trial and site-level data into outputs that are not only technically informed, but also clinically grounded and operationally useful.
That means the output is designed to be:
Team
Led by experts in medicine, clinical research, and AI
Catχi brings together clinical-trial perspective and technical analysis to support better site-selection decisions.
Dora Morozova, MD
Board-certified hematologist with more than 7 years of scientific experience, clinical-trials expertise, and recognition from the European Society on Thrombosis and Haemostasis.
Alex Martyanov, PhD
Biophysicist and computer-vision specialist recognized by the American Society of Hematology, with more than 40 publications.
Start with a study-specific review
If you are planning a trial or already recruiting and want a more structured view of site-selection risk, Catχi can start with a focused review of your study context and provide a practical recommendation set.